All above 15 m 15-m amplitude images were electronically zoomed from an original 30 m 30-m scan. The sequential formation of the AnxA5 patches was further visualized by stepwise additions of 2GPI, followed by AnxA5 and then aPL mAb, performed in the absence and presence of HCQ (Figure 7A-H). binding of antiphospholipid antibodies, increased cell-surface AnxA5 concentrations, and prolonged plasma Calcipotriol monohydrate coagulation to control levels. In Rabbit Polyclonal to HEY2 addition, HCQ increased the AnxA5 anticoagulant activities of APS patient plasmas. In conclusion, HCQ reversed antiphospholipid-mediated disruptions of AnxA5 on PLBs and cultured cells, and in APS patient plasmas. These results support the concept of novel therapeutic approaches that address specific APS disease mechanisms. == Introduction == The Calcipotriol monohydrate antiphospholipid (aPL) syndrome (APS), an autoimmune thrombophilic disorder, is believed to affect approximately 10% of patients who have vascular thrombosis1and approximately 20% of patients with recurrent spontaneous pregnancy losses.2Prevention of recurrent thrombosis in APS requires long-term anticoagulant therapy,3a treatment associated with the risk of hemorrhagic complications.3The elucidation of specific mechanisms by which antiphospholipid antibodies may promote thrombosis may be useful for targeting treatment to earlier steps in the APS disease process. The aPL antibody-mediated disruption of the annexin A5 (AnxA5) anticoagulant shield is a thrombogenic mechanism for APS for which substantial evidence has accumulated.4AnxA5, which had been isolated from tissues as a vascular anticoagulant protein5and as a placental anticoagulant protein,6exhibits high affinity for anionic phospholipids.5,6Its potent anticoagulant properties result from its forming 2-dimensional crystals over phospholipid bilayers,7thereby shielding them from availability for critical coagulation enzyme reactions.5aPL antibodies interfere with AnxA5 binding,811and with its ordered crystallization,12thereby accelerating coagulation reactions.8,12This aPL antibody-mediated reduction of AnxA5 has also been demonstrated on placental trophoblasts,1315endothelial cells,14,16and platelets.8,11The interference with AnxA5 anticoagulant activity has been correlated with aPL antibodies that recognize a specific epitope on domain I of 2-glycoprotein I (2GPI),17considered to be the central protein recognized by aPL antibodies18, which is associated with increased risk of thrombosis. Assays of blood samples for AnxA5 binding8,9,11,19,20and anticoagulant activity8,20,21showed significant reductions in patients with APS and Calcipotriol monohydrate thrombosis, and also in patients with histories for recurrent pregnancy losses.22 Hydroxychloroquine (HCQ) is a synthetic antimalarial compound that has proven to be an effective immunosuppressive treatment of systemic lupus erythematosus (SLE).2326A reduction in the frequency of thrombosis among SLE patients treated with HCQ was first suggested more than 20 years ago27and buttressed by further evidence in patients with SLE2830and APS.30,31The Hopkins Lupus Cohort reported that the presence of aPL antibodies is an independent predictor of thrombosis in SLE, and that treatment of SLE patients with HCQ was associated with a reduced risk of thrombosis.28A cross-sectional study that compared aPL antibodypositive patients with thrombosis with a group of patients having the antibodies, but who did not have Calcipotriol monohydrate thrombotic histories, indicated that HCQ may be protective against thrombosis.31An observational study of a prospective cohort of SLE patients reported a strong and independent antithrombotic effect of antimalarials in a time-varying Cox model.32Another prospective study of patients in a lupus clinic who did not have a prior history of thrombotic manifestations indicated that aPL positivity was a risk factor for thrombosis with a hazard ratio of 5.87 for subsequent thrombosis compared with the aPL-negative SLE patients, and that treatment with HCQ reduced the hazard ratio for thrombosis/month to 0.99;30interestingly, the risk of thrombosis was also reduced in the aPL-negative group. A recent systematic review of the literature on antimalarial treatment in SLE concluded that there was moderate evidence for protection against thrombosis.33The drug significantly reduced the extent of experimentally provoked thrombosis in an animal model of APS, 34and also reversed aPL-mediated platelet activation.35We recently demonstrated that HCQ reduces the binding of aPL immunoglobulin G (IgG)2GPI complexes to phospholipid bilayers, and through atomic force Calcipotriol monohydrate microscopic (AFM) imaging studies, that the drug can disintegrate aPL-2GPI complexes.36 These effects of HCQ prompted us to investigate whether the drug might protect the binding of AnxA5 from disruption by aPL IgG-2GPI. We investigated this question with purified proteins and phospholipids, with cultured human umbilical vein endothelial cells (HUVECs), with a cultured syncytialized trophoblast cell (STC) line, and with human APS plasma samples. == Methods == == Reagents == The research protocol was approved by the institutional review board of Montefiore Medical Center, which granted permission for the use of.